EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Circulating lung cancer biomarkers: From translational research to clinical practice

Xu Qian, Qing-He Meng

Tumor Biology · 19.03.2024 · 46 (s1) · S27-S33

DOI: 10.3233/tub-230012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Tumor Biology, online erschienen am 28.10.2023. Verfasst von Xu Qian und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fundamental studies on biomarkers as well as developed assays for their detection can provide valuable information facilitating clinical decisions. For patients with lung cancer, there are established circulating biomarkers such as serum progastrin-releasing peptide (ProGRP), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCC-Ag), carcinoembryonic antigen (CEA), and cytokeratin-19 fragment (CYFRA21-1). There are also molecular biomarkers for targeted therapy such as epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) gene, KRAS gene, and BRAF gene. However, there is still an unmet need for biomarkers that can be used for early detection and predict treatment response and survival. In this review, we describe the lung cancer biomarkers that are currently being used in clinical practice. We also discuss emerging preclinical and clinical studies on new biomarkers such as omics-based biomarkers for their potential clinical use to detect, predict, or monitor subtypes of lung cancer. Additionally, between-method differences in tumor markers warrant further development and improvement of the standardization and harmonization for each assay.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsHumansBiomarkers, TumorTranslational Research, BiomedicalAntigens, NeoplasmCarcinoembryonic AntigenKeratin-19Phosphopyruvate HydrataseLung

Stichwörter der Autor:innen

Circulating tumor markerscirculating tumor DNAexosomeslung cancer diagnosticsnon-small cell lung carcinomasmall-cell lung carcinoma

Substanzen

antigen CYFRA21.1Biomarkers, TumorAntigens, NeoplasmCarcinoembryonic AntigenKeratin-19Phosphopyruvate Hydratase

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China.
  • Department of Laboratory Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Zitieren

APA

Qian, X., & Meng, Q. H. (2024). Circulating lung cancer biomarkers: From translational research to clinical practice. Tumor Biology, 46(s1), S27-S33. https://doi.org/10.3233/tub-230012

Vancouver

Qian X, Meng QH. Circulating lung cancer biomarkers: From translational research to clinical practice. Tumor Biology. 2024;46(s1):S27-S33. doi:10.3233/tub-230012

BibTeX
@article{Qian2024,
  author = {Qian, Xu and Meng, Qing-He},
  title = {Circulating lung cancer biomarkers: From translational research to clinical practice},
  journal = {Tumor Biology},
  year = {2024},
  volume = {46},
  number = {s1},
  pages = {S27--S33},
  doi = {10.3233/tub-230012}
}
Kostenlos starten →